Pfizer’s Abrysvo is designed to prevent RSV-associated disease in infants
Category: World Health Organization
Approximately 8.2 million people were diagnosed with the infectious disease in 2023
The decision is expected to facilitate timely access to Bavarian Nordic’s Imvanex